Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 31-39 , October 2004

Acute-phase proteins and microalbuminuria among patients with type 2 diabetes

Received 28 January 2003 ,Revised 15 July 2003 ,Accepted 6 February 2004.

References 

  1. Alzaid AA. Microalbuminuria in patients with NIDDM: an overview. Diab. Care. 1996;19:79–89
  2. Ritz E, Stefanski A. Diabetic nephopathy in type II diabetes. Am. J. Kidney Dis. 1996;27:167–194
  3. Kilaru P, Bakris GL. Renal mortality associated with non-insulin-dependent diabetes mellitus. J. Diab. Compl. 1997;11:104–111
  4. Schmitz A. Renal function changes in middle-aged and elderly Caucasian Type 2 (non-insulin-dependent) diabetic patients—a review. Diabetologia. 1993;36:985–992
  5. Groop L, Ekstrand A, Forsblom C, Widen E, Groop P-H, Teppo A-M, et al. Insulin resistance, hypertension and microalbuminuria in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36:642–647
  6. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736–741
  7. Kuller LH, Tracy RP, Shaten J. Meilahn EN for the MRFIT, relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Am. J. Epidemiol. 1996;144:537–547
  8. Stec JJ, Silbershatz H, Tofler GH, et al.  Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation. 2000;102:1634–1638
  9. Lowe GDO, Yarnel JWG, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischaemic heart disease in the speedwell study. Art Thromb. Vasc. Biol. 2001;21:603–610
  10. Ridcker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000;342:836–843
  11. Festa A, D’Agostino R, Howard G, MykkAnen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistence atherosclerosis study. Kidney Int. 2000;58:1703–1710
  12. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. WHO Monogr. Ser. 1982;56:162–165
  13. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation. 1960;21:1160–1175
  14. The Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure, Arch. Inter. Med. 153 (1993) 154–183.
  15. Friedwald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  16. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome x. Diabetologia. 1997;40:1286–1292
  17. Routledge PA. Clinical relevance of alpha 1 acid glycoprotein in health and disease. Progr. Clin. Biol. Res. 1989;300:185–198
  18. Schmidt MI, Duncan BB, Sharret AR, Lindberg G, Savage PJ, Offenbacher S, et al. G. Heiss for the ARIC investigators markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. The Lancet. 1999;353:1649–1652
  19. Ito S, Tsuda A, Momotsu T. Urinary orosomucoid excretion rate in patients with non-insulin-dependent diabetes mellitus. Acta End (Copenh.). 1989;120:584–590
  20. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. Diabetologia. 2002;45:115–120
  21. M.B. Gomes, L.J. Piccirillo, V.G. Nogueira, H.J. Matos, Acute-phase proteins among patients with type 1 diabetes, Diabetes & Metabolism 29 (2003) 405–411.
  22. Poland DCW, Schalkwijk CG, Stehouwer CDA, Koeleman CAM, Hoft BVH, Van Dijk W. Increased α3-fucosylation of α1-acid glycoprotein in type 1 diabetic patients is related to vascular function. Glycoconjugate. 2001;18:261–268
  23. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes. 2002;51:1157–1165
  24. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 2003;111:1805–1812
  25. Raynaud E, Pérez-Martin A, Brun JF, Aissa-Benhaddad A, Fédou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis. 2000;150:365–370
  26. Raynaud E, Brun JF, Pérez-Martin A, Jaques M. Association between fibrinogen levels and insulin resistance. Diab. Care. 1998;21:2040–2041
  27. Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diab. Care. 1992;15:1245–1250
  28. Mennen LI, Balkau B, Royer B. Microalbuminuria and markers of the atherosclerotic process: the D.E.S.I.R. study. Atherosclerosis. 2001;154:163–169
  29. Knöbl P, Schernthaner G, Schnack C. Thrombogenic factors are related to urinary albumin excretion rate in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1045–1050
  30. Bruno G, Perin PC, Bargero G, Borra M, D’errico N, Pagano G. Association of fibrinogen with glycaemic control and albumin excretion rate in patientes with non-insulin-dependent diabetes mellitus. Ann. Inter. Med. 1996;125:653–657
  31. Mcmilllan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism. 1989;38:1042–1048
  32. Rodrı́guez-Morán M, Guerrero-Romero F. Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J. Diab. Compl. 1999;13:211–215
  33. Knöbl P, Schernthaner G, Schnack C. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb. Haemost. 1994;71:692–697
  34. Feo PD, Gaisano MG, Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis humans. J. Clin. Invest. 1991;88:833–840
  35. Ceriello A, Taboga C, Giacomello R. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes. 1994;43:430–432
  36. C. Gabay, I. Kushner, Acute-phase proteins and other systemic responses to inflammation, N. Engl. J. Med. 340 (1999) 448–454.
  37. Ceriello A. Fibrinogen and diabetes mellitus: is it time for intervention trials?. Diabetologia. 1997;40:731–734
  38. Collier A, Rumley A, Rumley AG. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes. 1992;41:909–913
  39. Jager A, Van Hinsberg VWM, Kostene PJ. C-reactive protein and soluble vascular cell adhesion molecule 1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2002;22:593–598

PII: S0168-8227(04)00053-1

doi: 10.1016/j.diabres.2004.02.009

Diabetes Research and Clinical Practice
Volume 66, Issue 1 , Pages 31-39 , October 2004

Article Tools

* Image Usage & Resolution